Joinn Laboratories (China) (HKG:6127) reported 19.8 million yuan in third-quarter attributable profit, down 80% year on year, according to a Hong Kong bourse filing Thursday.
Earnings per share fell 77% to 0.03 yuan.
The drug research company's revenue fell nearly 35% year-on-year to 316.4 million yuan, figures showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.